Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Taiho Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Taiho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Taiho Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Taiho Pharmaceutical Co., Ltd.'s pipeline products Reasons to buy - Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Taiho Pharmaceutical Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Taiho Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Taiho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taiho Pharmaceutical Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Taiho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Taiho Pharmaceutical Co., Ltd. Snapshot 6 Taiho Pharmaceutical Co., Ltd. Overview 6 Key Information 6 Key Facts 6 Taiho Pharmaceutical Co., Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Taiho Pharmaceutical Co., Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance 15 Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Taiho Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Taiho Pharmaceutical Co., Ltd. - Drug Profiles 21 (piperacillin sodium + tazobactam sodium) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 (tegafur + gimeracil + oteracil) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (tipiracil + trifluridine) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 orantinib 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 TAS-118 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 bilastine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 TAS-106 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 paclitaxel 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 TAS-120 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ARH-1029 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 TAS-114 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TAS-115 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 TAS-116 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 TAS-117 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 TAS-2104 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TAS-2913 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TAS-2985 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 TAS-5567 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecule to Inhibit S100B-p53 Interaction for Melanoma 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis 46 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target 46 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 48 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 49 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 50 Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates 52 Taiho Pharmaceutical Co., Ltd. - Dormant Projects 62 Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 63 Discontinued Pipeline Product Profiles 63 suplatast tosilate 63 Taiho Pharmaceutical Co., Ltd. - Company Statement 64 Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 65 Head Office 65 Other Locations & Subsidiaries 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 67 Disclaimer 67
List of Tables Taiho Pharmaceutical Co., Ltd., Key Information 6 Taiho Pharmaceutical Co., Ltd., Key Facts 6 Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 8 Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 10 Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 11 Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12 Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 13 Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14 Taiho Pharmaceutical Co., Ltd. - Phase III, 2014 15 Taiho Pharmaceutical Co., Ltd. - Phase II, 2014 16 Taiho Pharmaceutical Co., Ltd. - Phase I, 2014 17 Taiho Pharmaceutical Co., Ltd. - Preclinical, 2014 18 Taiho Pharmaceutical Co., Ltd. - Discovery, 2014 19 Taiho Pharmaceutical Co., Ltd. - Unknown, 2014 20 Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 47 Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 48 Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 49 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 51 Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 52 Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 62 Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 63 Taiho Pharmaceutical Co., Ltd., Subsidiaries 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
